Today, BioCryst Pharmaceuticals, announced it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the oral, once-daily treatment ORLADEYO® (berotralstat), which is approved in Canada for the routine prevention of attacks HAE in adults and pediatric patients 12 years of age and older.
This means that BioCryst is now able to work towards implementing public funding for ORLADEYO for eligible HAE patients. This is truly exciting news as it means Canadian HAE patients are one step closer to gaining access to the first oral medication to treat HAE. There is still advocating work to be done and HAE Canada is dedicated to help Canadian patients gain access to this new treatment.
Please click here to read BioCryst’s press release.
Please click here to read about the news in the Angioedema News article.